ORLANDO, Fla., Aug. 19, 2015 (GLOBE NEWSWIRE) -- RedChip Companies, Inc., today announced it has issued a research profile on Immuron Limited (ASX:IMC), a biopharmaceutical company focused on immunotherapy using dairy-derived antibody products for humans.
Highlights of the report include:
Current revenue generated from Travelan, an all-natural OTC product for the prevention of travelers' diarrhea (TD). Travelan is an all-natural OTC product currently sold for the prevention of TD. Travelan reduces the risk of TD, along with the symptoms of minor gastrointestinal disorders. Travelan is currently the only therapy that prevents TD by 90%, and the product also has a very high safety profile. Two independent, double-blinded, placebo-controlled clinical trials in Europe in 90 healthy volunteers showed protection of more than 90% against infection with the type of E.coli that causes TD, along with indicating a significant reduction in abdominal cramps and stomach pain. There were no reported side effects in the clinical trials.
Launching the product in bigger markets could lead to a significant increase in sales. In late 2011, research indicated that 79% of Americans would purchase a preventative dietary supplement that protects against TD if it was available. In FY14, Travelan generated A$1.0 million in revenue, and we believe that significant increases in revenue could occur in the future if the product is licensed in bigger markets such as the U.S. Already, Immuron has received a 50,000 packet order from its first nonexclusive distributor in the U.S. This should generate, at a minimum, at least an additional A$1 million in revenue. The Company is going to focus its initial U.S. product launch on travel clinics and alternative health clinics; this will require a low sales and marketing spend, while putting the product in venues that are likely to generate significant sales.
Immuron's hyper-immune platform technology is safe, low cost, and can be applied to a variety of diseases. Immuron's platform technology is based on producing hyper-immune bovine colostrum powder (BCP) suitable for pharmaceutical use. Large amounts of BCP can be generated in approximately four months, which should ensure low production costs and quick manufacturing of the Company's products. The underlying nature of Immuron's platform technology enables the development of medicines across a large range of diseases, including infectious diseases, immune mediated disorders, and cancers. This is due to the platform's versatility. It can be used to influence the cell-mediated immune system through regulatory T cell populations, or it can directly block viruses or bacteria at mucosal surfaces (such as the GI tract). Additionally, the dairy origins of Immuron's antibodies enables the company to commercialize its platform through most regulatory pathways, including prescription (Rx), medical foods, over-the-counter medicines, and dietary supplements.
Promising Phase 1/2a clinical trial results in NASH (IMM-124E). IMC conducted an open-label trial in 10 subjects with biopsy proven NASH and insulin resistance or type II diabetes. The patients were orally treated for 30 days (600 mg a day). IMM-124E showed an immunomodulatory effect in subjects with insulin resistance or type II diabetes, hyperlipidemia, and NASH.
In aggregate, the study showed a lot of positive results across a wide spectrum of indicators. We believe that the wide ranging positive results provide further optimism for success in a larger Phase IIb clinical trial.
To receive a complimentary copy of the full RedChip Research Report for IMC, please visit: http://www.redchip.com/assets/reports/Immuron_ResearchProfile_20150817.pdf
About RedChip Companies, Inc.
RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit:
http://www.redchip.com/our_services
"Discovering Tomorrow's Blue Chips Today"™
Disclosure
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. Immuron Ltd. (IMC) is a client of RedChip Companies, Inc. IMC agreed to pay RedChip Companies, Inc. a monthly cash fee, 250,000 shares of Rule 144 stock for its first year service of capital markets consulting services, and 250,000 shares of rule 144 stock for twenty-four (24) months of investor awareness services. Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.